SCHEMBL24902109

SCHEMBL24902109

CC(C(=O)n1ccc2c(-c3cnn([C@H](CC#N)C4CCCC4)c3)ncnc21)c1cccc(Oc2ccccc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 11/20 0.48
JAK1 P23458 9/20 0.48
JAK3 P52333 4/20 0.48
TYK2 P29597 3/20 0.48
ABL1 P00519 3/20 0.48
DAPK3 O43293 2/20 0.48
PAK4 O96013 2/20 0.48
RET P07949 2/20 0.48
LTK P29376 2/20 0.48
CSNK1A1 P48729 2/20 0.48
CLK2 P49760 2/20 0.48
TNK2 Q07912 2/20 0.48
ROCK1 Q13464 2/20 0.48
DYRK1A Q13627 2/20 0.48
IKBKE Q14164 2/20 0.48
NTRK3 Q16288 2/20 0.48
NTRK2 Q16620 2/20 0.48
LRRK2 Q5S007 2/20 0.48
TAOK1 Q7L7X3 2/20 0.48
CAMK1D Q8IU85 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26610814 1.00 JAK2 (0.48) JAK2JAK1JAK3TYK2ABL1
SCHEMBL30223528 0.90 JAK2 (0.49) JAK2JAK1JAK3TYK2ABL1
SCHEMBL27200378 0.90 JAK2 (0.49) JAK2JAK1JAK3TYK2ABL1
SCHEMBL24902064 0.90 JAK2 (0.49) JAK2JAK1JAK3TYK2ABL1
SCHEMBL30864377 0.89 JAK2 (0.47) JAK2JAK1JAK3TYK2ABL1
SCHEMBL24902015 0.89 JAK2 (0.47) JAK2JAK1JAK3TYK2ABL1
SCHEMBL26610240 0.88 JAK2 (0.46) JAK2JAK1JAK3TYK2ABL1
SCHEMBL24902065 0.87 JAK2 (0.48) JAK2JAK1JAK3TYK2ABL1
SCHEMBL30223585 0.87 JAK2 (0.48) JAK2JAK1JAK3TYK2ABL1
SCHEMBL26610819 0.87 JAK2 (0.48) JAK2JAK1JAK3TYK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250241922-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) 2025-07-31 US disclosed
US-20250241921-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) 2025-07-31 US disclosed
US-12290519-B2 Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2025-05-06 US disclosed
US-20240197741-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) 2024-06-20 US disclosed
CN-117355527-B Anti-inflammatory coupling compound medicine and preparation method and application thereof 上海椿安生物医药科技有限公司 2024-06-07 CN disclosed
EP-4357346-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF Coval Biopharma (Shanghai) Co., Ltd. (CN) 2024-04-24 EP disclosed
CN-117355527-A External anti-inflammatory coupling compound medicine and preparation method and application thereof 上海椿安生物医药科技有限公司 2024-01-05 CN disclosed
WO-2023001045-A9 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-10-26 WO disclosed
WO-2023001045-A9 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-10-26 WO disclosed
WO-2023001045-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-01-26 WO disclosed
WO-2023001045-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250241921-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF JAK1, TNF, CYP4A11 JAK2 4/4885JAK1 1/4885JAK3 20/4885
US-12290519-B2 Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof JAK1, TNF, CYP4A11 JAK2 4/4885JAK1 1/4885JAK3 20/4885
US-20250241922-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF JAK1, TNF, CYP4A11 JAK2 4/4885JAK1 1/4885JAK3 20/4885
US-20240197741-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF TNF, CYP4A11, JAK1 JAK2 4/4885JAK1 3/4885JAK3 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.